Feline Bordetella bronchiseptica Vaccine
AVIRULENT LIVE CULTURE
Research has demonstrated that B. bronchiseptica acts as a primary or secondary pathogen in feline respiratory disease. Traditionally, feline herpesvirus (FHV) and feline calicivirus (FCV) have been implicated as the most common agents associated with feline upper respiratory infection (URI). However, studies have shown that B. bronchiseptica may be the sole infectious agent in feline URI.1,2 Clinical signs associated with B. bronchiseptica infection may include fever, sneezing, nasal discharge, coughing and submandibular lymphadenopathy. In some cases, the infection progresses to pneumonia. Research regarding interspecies transmission has demonstrated isolates from cats and dogs housed in the same location were similar if not identical.3 Because B. bronchiseptica is transmitted by the aerosol route, animals in close confinement such as in catteries, boarding facilities, hospitals or pet stores, or cats from multi-cat households are at greatest risk for infection.
PROTEX®-Bb is an INTRANASAL vaccine containing an avirulent live culture of Bordetella bronchiseptica. PROTEX®-Bb is presented in a desiccated form with sterile diluent provided for reconstitution.
PROTEX®-Bb is for vaccination of healthy kittens and cats for prevention of disease caused by B. bronchiseptica.
Aseptically reconstitute the desiccated vaccine with the sterile diluent provided. REMOVE THE NEEDLE AND ADMINISTER 0.2 mL INTRANASALLY. Healthy kittens four weeks of age or older should be vaccinated prior to confinement or when risk of exposure to B. bronchiseptica may exist.
Recommended storage temperature 35 to 45o F (2 to 7oC).
Shake well before use.
Use contents promptly once reconstituted. Non-chemically sterilized needles and syringes should be used for administration of vaccine.
Burn this container and all unused contents.
Only healthy animals should be vaccinated. Animals incubating any disease, or animals stressed due to shipping, malnutrition or parasitism may not achieve or maintain an adequate immune response.
Administration of epinephrine may be indicated in the event of an anaphylactic reaction.